Literature DB >> 9468557

A human lung cancer xenograft producing granulocyte-colony stimulating factor and parathyroid hormone-related protein.

Y Oshika1, M Nakamura, H Hatanaka, Y Abe, T Tokunaga, Y Ohnishi, H Kijima, H Yamazaki, N Tamaoki, Y Ueyama.   

Abstract

A human lung cancer xenograft, LC-GP, producing granulocyte-colony stimulating factor and parathyroid hormone-related protein was established by transplantation into severe combined immunodeficient (SCID) mice. The lung cancer patient and SCID mice bearing LC-GP showed leukocytosis and hypercalcemia. G-CSF and PTHrP gene expression were demonstrated in the primary lung cancer, metastatic lesions and LC-GP xenograft. Immunohistochemical analysis confirmed the presence of G-CSF protein in LC-GP xenograft cells. LC-GP possessed activated c-Ki-ras oncogene (point mutation at codon 12). This LC-GP lacked apparent G-CSF receptor expression. The expression of G-CSF and PTHrP may be coregulated by the activated c-Ki-ras oncogene, and autocrine stimulation of G-CSF is unlikely.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9468557     DOI: 10.3892/or.5.2.359

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  Regulation of granulocyte colony-stimulating factor and parathyroid hormone-related protein production in lung carcinoma cell line OKa-C-1.

Authors:  Y Uemura; H Nakata; M Kobayashi; R Harada; Y Asahi; H Taguchi
Journal:  Jpn J Cancer Res       Date:  2000-09

2.  Granulocyte-colony stimulating factor-producing uterine cervical cancer treated with chemoradiotherapy: A case report with mutation analysis and literature review.

Authors:  Shintaro Shiba; Takahiro Oike; Ken Ando; Yuya Yoshimoto; Yoshiyasu Takayama; Tatsuya Ohno
Journal:  Clin Case Rep       Date:  2020-11-06

3.  MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data.

Authors:  Xiang Tan; Mingwu Chen
Journal:  Tumour Biol       Date:  2014-09-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.